Retinal image-based deep learning for mild cognitive impairment detection in coronary artery disease population

基于视网膜图像的深度学习在冠状动脉疾病人群轻度认知障碍检测中的应用

阅读:1

Abstract

BACKGROUND: Coronary artery disease (CAD) is linked to an increased risk of mild cognitive impairment (MCI). Effective and convenient screening methods for identifying MCI from the CAD population are still lacking. This study aims to develop a deep learning model using fundus images to optimise MCI diagnosis in the CAD population, achieving early intervention and improving prognosis. METHODS: Patients with CAD (at least one ≥50% stenosis) from July 2021 to July 2023 at Beijing Anzhen Hospital were included in the single-centre cross-sectional study. Eligible patients from July 2021 to May 2023 were randomly assigned in an 8:2 ratio for training and internal testing of the model. Patients enrolled from June 2023 to July 2023 were included in the external validation group. Four different convolutional neural network architectures were used to train the subjects' fundus images. The reference standards were a Mini-Mental State Examination (MMSE) score of <27 and a Montreal Cognitive Assessment (MoCA) score of <26, respectively. A comprehensive visual model of MCI detection was established through model integration. RESULTS: A total of 9009 eligible images from 4357 patients with CAD were collected. The artificial intelligence (AI) algorithm based on the MMSE achieved an area under the curve (AUC) of 0.832 (95% CI 0.800 to 0.863) in the test group and 0.776 (95% CI 0.730 to 0.821) in the validation group. The AI algorithm based on the MoCA achieved an AUC of 0.764 (95% CI 0.742 to 0.785) in the test group and 0.725 (95% CI 0.701 to 0.750) in the validation group. The calibration curves of the internal test sets of the two models exhibited a good calibration effect. The results of decision curves revealed extensive clinical application value. CONCLUSION: The AI algorithm trained on fundus images in this study exerted promising performance in screening MCI in the CAD population and might be a non-invasive and effective alternative for early diagnosis of the disease. TRIAL REGISTRATION NUMBER: NCT06102226.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。